Solid Biosciences Inc expected to post a loss of 60 cents a share - Earnings Preview

Reuters03-07

Solid Biosciences Inc SLDB.OQ SLDB.O is expected to show no change in quarterly revenue when it reports results on May 13 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Solid Biosciences Inc is for a loss of 60 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 0.9% in the last three months.
Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00, above its last closing price of $5.50.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Dec. 31 2024	-0.81	-0.81	-1.00	Missed	-24
Sep. 30 2024	-0.66	-0.67	-0.79	Missed	-18.3
Jun. 30 2024	-0.66	-0.66	-0.61	Beat	8.1
Mar. 31 2024	-0.65	-0.64	-0.64	Met	-0.1
Dec. 31 2023	-1.04	-0.99	-1.00	Missed	-1.2
Sep. 30 2023	-1.19	-1.19	-1.05	Beat	11.6
Jun. 30 2023	-1.55	-1.53	-1.25	Beat	18.6
Mar. 31 2023	-2.21	-2.05	-1.50	Beat	26.9

This summary was machine generated March 7 at 13:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2517264480?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-07 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517264480","market":"nz","top_or_hot":-1,"title":"Solid Biosciences Inc  expected to post a loss of 60 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/SLDB\">Solid Biosciences</a> Inc <sldb.oq> expected to post a loss of 60 cents a share - Earnings Preview </sldb.oq></title></head><body><ul><li><p>Solid Biosciences Inc <span>SLDB.OQ</span> <span>SLDB.O</span> is expected to show no change in quarterly revenue when it reports  results on May 13 (estimated) for the period ending March 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Solid Biosciences Inc is for a loss of 60 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts had fallen by about 0.9% in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00, above its last closing price of $5.50. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>-0.81</p></td><td><p>-0.81</p></td><td><p>-1.00</p></td><td><p>Missed</p></td><td><p>-24</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-0.66</p></td><td><p>-0.67</p></td><td><p>-0.79</p></td><td><p>Missed</p></td><td><p>-18.3</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-0.66</p></td><td><p>-0.66</p></td><td><p>-0.61</p></td><td><p>Beat</p></td><td><p>8.1</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-0.65</p></td><td><p>-0.64</p></td><td><p>-0.64</p></td><td><p>Met</p></td><td><p>-0.1</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-1.04</p></td><td><p>-0.99</p></td><td><p>-1.00</p></td><td><p>Missed</p></td><td><p>-1.2</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-1.19</p></td><td><p>-1.19</p></td><td><p>-1.05</p></td><td><p>Beat</p></td><td><p>11.6</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>-1.55</p></td><td><p>-1.53</p></td><td><p>-1.25</p></td><td><p>Beat</p></td><td><p>18.6</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td><p>-2.21</p></td><td><p>-2.05</p></td><td><p>-1.50</p></td><td><p>Beat</p></td><td><p>26.9</p></td></tr></tbody></table><p>This summary was machine generated March 7 at 13:17 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Solid Biosciences Inc  expected to post a loss of 60 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSolid Biosciences Inc  expected to post a loss of 60 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-07 21:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/SLDB\">Solid Biosciences</a> Inc <sldb.oq> expected to post a loss of 60 cents a share - Earnings Preview </sldb.oq></title></head><body><ul><li><p>Solid Biosciences Inc <span>SLDB.OQ</span> <span>SLDB.O</span> is expected to show no change in quarterly revenue when it reports  results on May 13 (estimated) for the period ending March 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Solid Biosciences Inc is for a loss of 60 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts had fallen by about 0.9% in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00, above its last closing price of $5.50. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>-0.81</p></td><td><p>-0.81</p></td><td><p>-1.00</p></td><td><p>Missed</p></td><td><p>-24</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-0.66</p></td><td><p>-0.67</p></td><td><p>-0.79</p></td><td><p>Missed</p></td><td><p>-18.3</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-0.66</p></td><td><p>-0.66</p></td><td><p>-0.61</p></td><td><p>Beat</p></td><td><p>8.1</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-0.65</p></td><td><p>-0.64</p></td><td><p>-0.64</p></td><td><p>Met</p></td><td><p>-0.1</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-1.04</p></td><td><p>-0.99</p></td><td><p>-1.00</p></td><td><p>Missed</p></td><td><p>-1.2</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-1.19</p></td><td><p>-1.19</p></td><td><p>-1.05</p></td><td><p>Beat</p></td><td><p>11.6</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>-1.55</p></td><td><p>-1.53</p></td><td><p>-1.25</p></td><td><p>Beat</p></td><td><p>18.6</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td><p>-2.21</p></td><td><p>-2.05</p></td><td><p>-1.50</p></td><td><p>Beat</p></td><td><p>26.9</p></td></tr></tbody></table><p>This summary was machine generated March 7 at 13:17 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLDB","symbol_name":"Solid Biosciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nL5N3PQ15E:1","article_id":"2517264480","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517264480","pubTimestamp":1741353442,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Solid Biosciences Inc  expected to post a loss of60cents a share - Earnings Preview Solid Biosciences Inc SLDB.OQ SLDB.O is expected to show no change in quarterly revenue when it reports  results on ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SLDB":"Solid Biosciences"},"translate_title":"Solid Biosciences Inc预计每股亏损60美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLDB":0.9},"content_text":"Solid Biosciences Inc  expected to post a loss of 60 cents a share - Earnings Preview Solid Biosciences Inc SLDB.OQ SLDB.O is expected to show no change in quarterly revenue when it reports  results on May 13 (estimated) for the period ending March 31 2025LSEG's mean analyst estimate for Solid Biosciences Inc is for a loss of 60 cents per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts had fallen by about 0.9% in the last three months. Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00, above its last closing price of $5.50. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Dec. 31 2024-0.81-0.81-1.00Missed-24Sep. 30 2024-0.66-0.67-0.79Missed-18.3Jun. 30 2024-0.66-0.66-0.61Beat8.1Mar. 31 2024-0.65-0.64-0.64Met-0.1Dec. 31 2023-1.04-0.99-1.00Missed-1.2Sep. 30 2023-1.19-1.19-1.05Beat11.6Jun. 30 2023-1.55-1.53-1.25Beat18.6Mar. 31 2023-2.21-2.05-1.50Beat26.9This summary was machine generated March 7 at 13:17 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517264480"}